Oncothyreon Inc (USA) (NASDAQ:ONTY) shares decline by 5.42%

1569

Boston, MA, 07/01/2013 (financialstrend) – Oncothyreon Inc (USA) (NASDAQ:ONTY) has been given worldwide license for the development, manufacture and commercialization of Stimuvax to Merck KGaA of Darmstadt, Germany (Merck KGaA), which in turn had enrolled 1514 patients in NSCLC. The company’s quarterly performance  was decreased by 24.34 percent and its year to date performance identifies the decrease in the stock value by 18.23 percent.

Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY) which opened at $1.65 had declined by 5.42 percent to end up the day at $1.57 on Friday. The decline in the share prices of the company is about $0.09 per share for the day. The price range of Oncothyreon Inc (USA) (NASDAQ:ONTY)   varied from as low as $1.55 to a peak value of $1.68. The total outstanding shares of the company are 57.22 million shares which accounts for a huge market capitalization of 89.83 million for Oncothyreon Inc (USA) (NASDAQ:ONTY).

The 52 week low of the company is at $1.55 and the high value was $6.24. Trading volume of the shares of Oncothyreon Inc (USA) (NASDAQ:ONTY)   for last Friday was 9.00 million shares which was high when compared to the average trading volume of 1.09 million shares. The institutional investors of the company contribute for around 53 percent of the total outstanding shares.

Oncothyreon Inc (USA) (NASDAQ:ONTY) is a biopharmaceutical company whose primary focus is on the development of the therapeutic products for the treatment of cancer. Oncothyreon Inc (USA) (NASDAQ:ONTY)’s produces cancer vaccines which stimulate the immune system to attack cancer cells and also its small molecular compounds are designed to inhibit the activity of specific cancer related proteins. Stimuvax, which is one of the leading product of Oncothyreon Inc (USA) (NASDAQ:ONTY) is a cancer vaccines that is evaluated in two phase – III clinical trials for the treatment of non-small cell lung cancer (NSCLC).